Gitte Moos Knudsen
Overview
Explore the profile of Gitte Moos Knudsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
1425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen M, Stenbaek D, Messell C, Poulsen E, Varga T, Fisher P, et al.
J Psychopharmacol
. 2025 Feb;
:2698811251319457.
PMID: 40018886
Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects...
2.
Klausen M, Knudsen G, Vilsboll T, Fink-Jensen A
Basic Clin Pharmacol Toxicol
. 2025 Feb;
136(3):e70004.
PMID: 39891507
In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention....
3.
Bruzzone S, Ozenne B, MacDonald Fisher P, Ortega G, Jorgensen M, Knudsen G, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2024 Oct;
136():111160.
PMID: 39368538
Selective serotonin reuptake inhibitors (SSRI) are frequently ineffective in treating depressive episodes and biomarkers are needed to optimize antidepressant treatment outcomes. DNA methylation levels of serotonin transporter (SLC6A4) and tryptophan...
4.
Miskowiak K, Damgaard V, Schandorff J, Macoveanu J, Knudsen G, Johansen A, et al.
Trials
. 2024 Oct;
25(1):648.
PMID: 39363230
Background: Cognitive impairment is prevalent across neuropsychiatric disorders but there is a lack of treatment strategies with robust, enduring effects. Emerging evidence indicates that altitude-like hypoxia cognition training may induce...
5.
Zarifkar P, Wagner M, MacDonald Fisher P, Stenbaek D, Berg S, Knudsen G, et al.
Brain Commun
. 2024 Jul;
6(4):fcae174.
PMID: 39045091
Survival rates after out-of-hospital cardiac arrest have improved over the past two decades. Despite this progress, long-term cognitive impairment remains prevalent even in those with early recovery of consciousness after...
6.
Johansen A, Beliveau V, Colliander E, Raval N, Dam V, Gillings N, et al.
J Neurosci
. 2024 Jul;
44(33).
PMID: 38997157
Synapses are fundamental to the function of the central nervous system and are implicated in a number of brain disorders. Despite their pivotal role, a comprehensive imaging resource detailing the...
7.
Gronlund E, Lindberg U, Fisher P, Othman M, Amiri M, Solling C, et al.
Neurocrit Care
. 2024 Jun;
41(3):1027-1037.
PMID: 38918338
Background: To investigate patients with disorders of consciousness (DoC) for residual awareness, guidelines recommend quantifying glucose brain metabolism using positron emission tomography. However, this is not feasible in the intensive...
8.
Brendstrup-Brix K, Ulv Larsen S, Lee H, Knudsen G
J Sleep Res
. 2024 Apr;
33(6):e14226.
PMID: 38676409
The glymphatic system is centred around brain cerebrospinal fluid flow and is enhanced during sleep, and the synaptic homeostasis hypothesis proposes that sleep acts on brain microstructure by selective synaptic...
9.
Macoveanu J, Fortea L, Kjaerstad H, Coello K, Faurholt-Jepsen M, Fisher P, et al.
Psychol Med
. 2024 Apr;
54(11):2857-2865.
PMID: 38634498
Background: There is a significant contribution of genetic factors to the etiology of bipolar disorder (BD). Unaffected first-degree relatives of patients (UR) with BD are at increased risk of developing...
10.
Macoveanu J, Petersen J, Mariegaard J, Jespersen A, Cramer K, Bruun C, et al.
J Psychopharmacol
. 2024 Mar;
38(4):362-374.
PMID: 38519416
Background: Persistent cognitive impairment is frequent across bipolar disorder (BD) and major depressive disorder (MDD), highlighting an urgent need for pro-cognitive treatments. Aim: This study investigated effects of erythropoietin (EPO)...